COVID 19, Juvenile Idiopathic Arthritis, Treatment
Conditions
Brief summary
The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Juvenile Idiopathic Arthritis is concerns by these fears (the patient and their parents). Patients are treated by several classes of immunomodulatory drugs, including non-steroidal anti-inflammatory drugs, corticosteroids and disease modifying anti-rheumatic drugs. The present study will characterize this issue by defining the proportion of patients whose usual treatment of Juvenile Idiopathic Arthritis has been modified in relation to the actual sanitary crisis, and also to return to school.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* Juvenile Idiopathic Arthritis satisfying Edmonton criteria * Ongoing DMARD therapy or AINS for 3 months
Exclusion criteria
* Inhability to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis | 1 Day | Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD |
Countries
France
Contacts
Primary ContactValerie DEVAUCHELLE
Backup ContactValerie DEVAUCHELLE
Outcome results
None listed